Summary

Pharmaceutical Contract Development And Manufacturing Organization Market Summary

The global pharmaceutical contract development and manufacturing organization market size was estimated at USD 155.5 billion in 2024 and is projected to reach USD 293.6 billion by 2033, growing at a CAGR of 7.38% from 2025 to 2033. Growth in the market can be attributed to the rising investments by CDMOs to expand new drug development and the increasing demand for novel therapies.

In addition, growing investments in pharmaceutical R&D, rising demand for genetic drugs, and growing prevalence of cancer & age-related disorders, coupled with increasing need for advanced therapeutics, are some of the key factors driving market growth.
The pharmaceutical industry is experiencing a significant shift from traditional small molecules to biopharmaceuticals. This includes monoclonal antibodies, vaccines, recombinant proteins, and other therapies such as mRNA treatments. In addition, this shift is driven by the growing prevalence of chronic diseases, an aging global population, and the increasing access to targeted therapies that tend to provide better efficacy and fewer side effects than conventional treatments.

According to the data published by IQVIA in January 2024, the global medicine spending at list prices is anticipated to rise by 38% between 2024 and 2028, with biologics accounting for more than 40% of that growth, reflecting the central role in the treatments. Regulators such as the U.S. FDA continue to clear record numbers of innovative biologics, approving 50 novel drugs in 2024, of which a significant proportion were advanced biologics and specialty medicines, supported by a 74% first-cycle approval rate that accelerates patient access. Also, biopharmaceuticals represent over half of the late-stage pipeline, and categories such as GLP-1 agonists for diabetes and obesity, cell and gene therapies for rare diseases, and monoclonal antibody–based cancer therapies are shaping demand trajectories. Therefore, CDMOs play an essential role in this environment as biologics production requires complex infrastructure, such as single-use bioreactors, continuous bioprocessing systems, and high-level cold chain logistics, all of which demand expertise and heavy capital investment.

Global Pharmaceutical Contract Development And Manufacturing Organization Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global pharmaceutical contract development and manufacturing organization market report based on type, product, service, workflow, therapeutic area, end use, and region.

• Type Outlook (Revenue, USD Million, 2021 - 2033)
• Small Molecule
o Branded
o Generic
• Large Molecule
o Biologics
o Biosimilar
• Product Outlook (Revenue, USD Million, 2021 - 2033)
• API
o Traditional Active Pharmaceutical Ingredient (Traditional API)
o Highly Potent Active Pharmaceutical Ingredient (HP-API)
o Biologics
o Others
• Drug Product
o Oral solid dose
o Semi-solid dose
o Liquid dose
o Others
• Service Outlook (Revenue, USD Million, 2021 - 2033)
• Contract Development
o Pre-formulation & Formulation Development Services
o Process Development & Optimization
o Analytical Testing & Method Validation
o Scale-up & Tech Transfer
• Contract Manufacturing
o API Manufacturing
o Finished Drug Products Manufacturing
• Packaging and Labelling
• Regulatory Affairs
• Others
• Workflow Outlook (Revenue, USD Million, 2021 - 2033)
• Clinical
• Commercial
• Therapeutic Area Outlook (Revenue, USD Million, 2021 - 2033)
• Oncology
• Infectious Diseases
• Neurological Disorders
• Cardiovascular Disease
• Metabolic Disorders
• Autoimmune Diseases
• Respiratory Diseases
• Ophthalmology
• Gastrointestinal Disorders
• Orthopedic Diseases
• Dental Diseases
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Small Pharmaceutical Companies
• Medium Pharmaceutical Companies
• Large Pharmaceutical Companies
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
o U.S.
o Canada
o Mexico
• Europe
o UK
o Germany
o France
o Italy
o Spain
o Denmark
o Sweden
o Norway
• Asia Pacific
o China
o India
o Japan
o Australia
o South Korea
o Thailand
• Latin America
o Brazil
o Argentina
• Middle East & Africa
o South Africa
o UAE
o Saudi Arabia
o Kuwait
o Qatar
o Oman

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Research Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Type
1.2.2. Product
1.2.3. Services
1.2.4. Workflow
1.2.5. Therapeutic Area
1.2.6. End Use
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. GVR’s Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.5. Information Or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity Flow Analysis
1.7.2. Top-Down Analysis
1.7.3. Botton-Up Approach
1.7.4. Multivariate Analysis
1.8. List Of Secondary Sources
1.9. List Of Abbreviations
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Pharmaceutical Contract Development and Manufacturing Organization Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Growing Consumption of Biopharmaceuticals
3.2.1.2. Increasing Demand for One-Stop-Shop CDMOS
3.2.1.3. Rising Demand for Advanced Therapeutics
3.2.1.4. Increasing Outsourcing Services by Pharmaceutical Companies
3.2.1.5. Upsurge in the Number Of Clinical Trials
3.2.2. Market Restraint Analysis
3.2.2.1. Compliance Issues While Outsourcing
3.2.2.2. Changing Scenarios Within Developing Countries
3.2.3. Market Opportunity Analysis
3.3. R&D Spending Analysis
3.3.1. Venture Capital & Government Funding Scenario
3.4. Industry Ecosystem Analysis
3.4.1. Demand Analysis
3.4.2. Supply Chain Analysis
3.5. Technology Landscape
3.6. Clinical Trial Volume Analysis, 2024
3.7. Pricing Analysis
3.8. Tariff and Trade Agreement Impact Analysis
3.9. Value Chain Analysis
3.9.1. Supply Trends
3.9.2. Demand Trends
3.10. Market Analysis Tools
3.10.1. Porter’s Five Force Analysis
3.10.2. PESTEL by SWOT Analysis
Chapter 4. Pharmaceutical Contract Development and Manufacturing Organization Market: Type Estimates & Trend Analysis
4.1. Pharmaceutical Contract Development and Manufacturing Organization Market, By Type: Segment Dashboard
4.2. Pharmaceutical Contract Development and Manufacturing Organization Market, By Type: Movement Analysis
4.3. Pharmaceutical Contract Development and Manufacturing Organization Market Estimates & Forecasts, By Type, 2021 - 2033 (USD Million)
4.4. Small Molecule
4.4.1. Small Molecule Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4.2. Branded
4.4.2.1. Branded Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4.3. Generic
4.4.3.1. Generic Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5. Large Molecule
4.5.1. Large Molecule Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5.2. Biologics
4.5.2.1. Biologics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5.3. Biosimilar
4.5.3.1. Biosimilar Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 5. Pharmaceutical Contract Development and Manufacturing Organization Market: Product Estimates & Trend Analysis
5.1. Pharmaceutical Contract Development and Manufacturing Organization Market, By Product: Segment Dashboard
5.2. Pharmaceutical Contract Development and Manufacturing Organization Market, By Product: Movement Analysis
5.3. Pharmaceutical Contract Development and Manufacturing Organization Market Estimates & Forecasts, By Product, 2021 - 2033 (USD Million)
5.4. API
5.4.1. API Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.4.2. Traditional Active Pharmaceutical Ingredient (Traditional API)
5.4.2.1. Traditional Active Pharmaceutical Ingredient (Traditional API) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.4.3. Highly Potent Active Pharmaceutical Ingredient (HP-API)
5.4.3.1. Highly Potent Active Pharmaceutical Ingredient (HP-API) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.4.4. Biologics
5.4.4.1. Biologics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.4.5. Others
5.4.5.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5. Drug Product
5.5.1. Drug Product Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5.2. Oral Solid Dose
5.5.2.1. Oral Solid Dose Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5.3. Semi-Solid Dose
5.5.3.1. Semi-Solid Dose Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5.4. Liquid Dose
5.5.4.1. Liquid Dose Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5.5. Others
5.5.5.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 6. Pharmaceutical Contract Development and Manufacturing Organization Market: Service Estimates & Trend Analysis
6.1. Pharmaceutical Contract Development and Manufacturing Organization Market, By Service: Segment Dashboard
6.2. Pharmaceutical Contract Development and Manufacturing Organization Market, By Service: Movement Analysis
6.3. Pharmaceutical Contract Development and Manufacturing Organization Market Estimates & Forecasts, By Service, 2021 - 2033 (USD Million)
6.4. Contract Development
6.4.1. Contract Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4.2. Pre-formulation & Formulation Development Services
6.4.2.1. Pre-formulation & Formulation Development Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4.3. Process Development & Optimization
6.4.3.1. Process Development & Optimization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4.4. Analytical Testing & Method Validation
6.4.4.1. Analytical Testing & Method Validation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4.5. Scale-up & Tech Transfer
6.4.5.1. Scale-up & Tech Transfer Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5. Contract Manufacturing
6.5.1. Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.2. API Manufacturing
6.5.2.1. API Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.3. Finished Drug Products Manufacturing
6.5.3.1. Finished Drug Products Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6. Packaging and Labelling
6.6.1. Packaging and Labelling Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7. Regulatory Affairs
6.7.1. Regulatory Affairs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.8. Others
6.8.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 7. Pharmaceutical Contract Development and Manufacturing Organization Market: Workflow Estimates & Trend Analysis
7.1. Pharmaceutical Contract Development and Manufacturing Organization Market, By Workflow: Segment Dashboard
7.2. Pharmaceutical Contract Development and Manufacturing Organization Market, By Workflow: Movement Analysis
7.3. Pharmaceutical Contract Development and Manufacturing Organization Market Estimates & Forecasts, By Workflow, 2021 - 2033 (USD Million)
7.4. Clinical
7.4.1. Clinical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5. Commercial
7.5.1. Commercial Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 8. Pharmaceutical Contract Development and Manufacturing Organization Market: Therapeutic Area Estimates & Trend Analysis
8.1. Pharmaceutical Contract Development and Manufacturing Organization Market, By Therapeutic Area: Segment Dashboard
8.2. Pharmaceutical Contract Development and Manufacturing Organization Market, By Therapeutic Area: Movement Analysis
8.3. Pharmaceutical Contract Development and Manufacturing Organization Market Estimates & Forecasts, By Therapeutic Area, 2021 - 2033 (USD Million)
8.4. Oncology
8.4.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5. Infectious Diseases
8.5.1. Infectious Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6. Neurological Disorders
8.6.1. Neurological Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.7. Cardiovascular Diseases
8.7.1. Cardiovascular Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.8. Metabolic Disorders
8.8.1. Metabolic Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.9. Autoimmune Diseases
8.9.1. Autoimmune Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.10. Respiratory Diseases
8.10.1. Respiratory Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.11. Ophthalmology
8.11.1. Ophthalmology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.12. Gastrointestinal Disorders
8.12.1. Gastrointestinal Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.13. Orthopedic Diseases
8.13.1. Orthopedic Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.14. Dental Diseases
8.14.1. Dental Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.15. Others
8.15.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 9. Pharmaceutical Contract Development and Manufacturing Organization Market: End-Use Estimates & Trend Analysis
9.1. Pharmaceutical Contract Development and Manufacturing Organization Market, By End-Use: Segment Dashboard
9.2. Pharmaceutical Contract Development and Manufacturing Organization Market, By End-Use: Movement Analysis
9.3. Pharmaceutical Contract Development and Manufacturing Organization Market Estimates & Forecasts, By End-Use, 2021 - 2033 (USD Million)
9.4. Small Pharmaceutical Companies
9.4.1. Small Pharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.5. Medium Pharmaceutical Companies
9.5.1. Medium Pharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.6. Large Pharmaceutical Companies
9.6.1. Large Pharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 10. Pharmaceutical Contract Development And Manufacturing Organization Market: Regional Estimates & Trend Analysis
10.1. Regional Market Dashboard
10.2. Regional Market Share Analysis, 2024 & 2033
10.3. North America
10.3.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.3.2. U.S
10.3.2.1. Key Country Dynamics
10.3.2.2. Competitive Scenario
10.3.2.3. Regulatory Framework
10.3.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.3.3. Canada
10.3.3.1. Key Country Dynamics
10.3.3.2. Competitive Scenario
10.3.3.3. Regulatory Framework
10.3.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.3.4. Mexico
10.3.4.1. Key Country Dynamics
10.3.4.2. Competitive Scenario
10.3.4.3. Regulatory Framework
10.3.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.4. Europe
10.4.1. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.4.2. UK
10.4.2.1. Key Country Dynamics
10.4.2.2. Competitive Scenario
10.4.2.3. Regulatory Framework
10.4.2.4. UK Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.4.3. Germany
10.4.3.1. Key Country Dynamics
10.4.3.2. Competitive Scenario
10.4.3.3. Regulatory Framework
10.4.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.4.4. France
10.4.4.1. Key Country Dynamics
10.4.4.2. Competitive Scenario
10.4.4.3. Regulatory Framework
10.4.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.4.5. Italy
10.4.5.1. Key Country Dynamics
10.4.5.2. Competitive Scenario
10.4.5.3. Regulatory Framework
10.4.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.4.6. Spain
10.4.6.1. Key Country Dynamics
10.4.6.2. Competitive Scenario
10.4.6.3. Regulatory Framework
10.4.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.4.7. Denmark
10.4.7.1. Key Country Dynamics
10.4.7.2. Competitive Scenario
10.4.7.3. Regulatory Framework
10.4.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.4.8. Sweden
10.4.8.1. Key Country Dynamics
10.4.8.2. Competitive Scenario
10.4.8.3. Regulatory Framework
10.4.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.4.9. Norway
10.4.9.1. Key Country Dynamics
10.4.9.2. Competitive Scenario
10.4.9.3. Regulatory Framework
10.4.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.5. Asia Pacific
10.5.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.5.2. China
10.5.2.1. Key Country Dynamics
10.5.2.2. Competitive Scenario
10.5.2.3. Regulatory Framework
10.5.2.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.5.3. India
10.5.3.1. Key Country Dynamics
10.5.3.2. Competitive Scenario
10.5.3.3. Regulatory Framework
10.5.3.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.5.4. Japan
10.5.4.1. Key Country Dynamics
10.5.4.2. Competitive Scenario
10.5.4.3. Regulatory Framework
10.5.4.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.5.5. Australia
10.5.5.1. Key Country Dynamics
10.5.5.2. Competitive Scenario
10.5.5.3. Regulatory Framework
10.5.5.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.5.6. South Korea
10.5.6.1. Key Country Dynamics
10.5.6.2. Competitive Scenario
10.5.6.3. Regulatory Framework
10.5.6.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.5.7. Thailand
10.5.7.1. Key Country Dynamics
10.5.7.2. Competitive Scenario
10.5.7.3. Regulatory Framework
10.5.7.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.6. Latin America
10.6.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.6.2. Brazil
10.6.2.1. Key Country Dynamics
10.6.2.2. Competitive Scenario
10.6.2.3. Regulatory Framework
10.6.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.6.3. Argentina
10.6.3.1. Key Country Dynamics
10.6.3.2. Competitive Scenario
10.6.3.3. Regulatory Framework
10.6.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.7. MEA
10.7.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.7.2. South Africa
10.7.2.1. Key Country Dynamics
10.7.2.2. Competitive Scenario
10.7.2.3. Regulatory Framework
10.7.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.7.3. UAE
10.7.3.1. Key Country Dynamics
10.7.3.2. Competitive Scenario
10.7.3.3. Regulatory Framework
10.7.3.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.7.4. Saudi Arabia
10.7.4.1. Key Country Dynamics
10.7.4.2. Competitive Scenario
10.7.4.3. Regulatory Framework
10.7.4.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.7.5. Kuwait
10.7.5.1. Key Country Dynamics
10.7.5.2. Competitive Scenario
10.7.5.3. Regulatory Framework
10.7.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.7.6. Qatar
10.7.6.1. Key Country Dynamics
10.7.6.2. Competitive Scenario
10.7.6.3. Regulatory Framework
10.7.6.4. Qatar Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.7.7. Oman
10.7.7.1. Key Country Dynamics
10.7.7.2. Competitive Scenario
10.7.7.3. Regulatory Framework
10.7.7.4. Oman Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 11. Competitive Landscape
11.1. Key Participant Categorization
11.1.1. Market Leaders
11.1.2. Emerging Players
11.2. Market Share/Assessment Analysis, 2024 (Heat Map Analysis)
11.3. Company Profiles
11.3.1. Thermo Fisher Scientific, Inc
11.3.1.1. Company Overview
11.3.1.2. Financial Performance
11.3.1.3. Service Benchmarking
11.3.1.4. Strategic Initiatives
11.3.2. Lonza
11.3.2.1. Company Overview
11.3.2.2. Financial Performance
11.3.2.3. Service Benchmarking
11.3.2.4. Strategic Initiatives
11.3.3. Recipharm AB
11.3.3.1. Company Overview
11.3.3.2. Financial Performance
11.3.3.3. Service Benchmarking
11.3.3.4. Strategic Initiatives
11.3.4. Catalent, Inc
11.3.4.1. Company Overview
11.3.4.2. Financial Performance
11.3.4.3. Service Benchmarking
11.3.4.4. Strategic Initiatives
11.3.5. WuXi AppTec, Inc
11.3.5.1. Company Overview
11.3.5.2. Financial Performance
11.3.5.3. Service Benchmarking
11.3.5.4. Strategic Initiatives
11.3.6. Samsung Biologics
11.3.6.1. Company Overview
11.3.6.2. Financial Performance
11.3.6.3. Service Benchmarking
11.3.6.4. Strategic Initiatives
11.3.7. Piramal Pharma Solutions
11.3.7.1. Company Overview
11.3.7.2. Financial Performance
11.3.7.3. Service Benchmarking
11.3.7.4. Strategic Initiatives
11.3.8. Siegfried Holding AG
11.3.8.1. Company Overview
11.3.8.2. Financial Performance
11.3.8.3. Service Benchmarking
11.3.8.4. Strategic Initiatives
11.3.9. Corden Pharma International
11.3.9.1. Company Overview
11.3.9.2. Financial Performance
11.3.9.3. Service Benchmarking
11.3.9.4. Strategic Initiatives
11.3.10. Cambrex Corporation
11.3.10.1. Company Overview
11.3.10.2. Financial Performance
11.3.10.3. Service Benchmarking
11.3.10.4. Strategic Initiatives
11.3.11. Delpharm
11.3.11.1. Company Overview
11.3.11.2. Financial Performance
11.3.11.3. Service Benchmarking
11.3.11.4. Strategic Initiatives
11.3.12. Jubilant Pharmova / HollisterStier
11.3.12.1. Company Overview
11.3.12.2. Financial Performance
11.3.12.3. Service Benchmarking
11.3.12.4. Strategic Initiatives
11.3.13. Eurofins CDMO
11.3.13.1. Company Overview
11.3.13.2. Financial Performance
11.3.13.3. Service Benchmarking
11.3.13.4. Strategic Initiatives
11.3.14. Almac Pharma Services
11.3.14.1. Company Overview
11.3.14.2. Financial Performance
11.3.14.3. Service Benchmarking
11.3.14.4. Strategic Initiatives